Publications by authors named "David Chain"

Claim this Profile
P
Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial.
Claire Emson, Joseph K Han, Claire Hopkins, Sara Asimus, Jennifer A Cann, David Chain

Br J Clin Pharmacol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, David Chain

J Clin Invest· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue.
Andrew G Chambers, David C Chain, Steve M Sweet, Zifeng Song, Philip L Martin

Clin Proteomics· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis.
Ahmad Akhgar, Dominic Sinibaldi, Lingmin Zeng, Alton B Farris, Jason Cobb, David Chain

Lupus Sci Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies.
Steve Sweet, David Chain, Wen Yu, Philip Martin, Marlon Rebelatto

Sci Rep· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Extraction from Parallel Reaction Monitoring to Quantify Background Peptides for Improved Normalization and Quality Control in Targeted Proteomics.
Andrew G Chambers, Steve M M Sweet, David Chain, Yeoun Jin Kim

Anal Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Zhen Pang, Nancy N Wu, Weiguang Zhao, David C Chain, Erica Schaffer

Obesity (Silver Spring)· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis